Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac disease
Candidate demonstrates Teva's commitment to bringing important new treatment options to underserved patient populations
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet. TEV-53408 is currently being evaluated in a Phase 2a trial to assess the efficacy and safety in adults with celiac disease.
Fast Track is an FDA process designed to facilitate development and expedite review of drugs to treat serious conditions and address unmet medical needs.
'The FDA's decision to grant Fast Track designation for TEV-53408, an investigational anti-IL-15 antibody therapy, reflects the promising nature of the treatment and the urgent unmet need of people living with celiac disease,' said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. 'Teva is driven by a commitment to innovation and this latest achievement gets us one step closer to providing promising, innovative treatment options for patients with chronic autoimmune diseases like celiac disease.'
TEV-53408 is an antibody designed to inhibit the activity of the cytokine, interleukin-15 (IL-15), to prevent intestinal damage and associated symptoms in individuals with celiac disease. This potential treatment is a testament to the growing strength of Teva's innovative pipeline and dedication to advancing treatments for immunological conditions, including celiac disease, which affects approximately 1% of the global population.1-3
About TEV-53408
TEV-53408 is an investigational monoclonal antibody that inhibits interleukin-15 (IL-15), which aims to reduce the immune response to gluten that causes intestinal inflammation and damage in individuals with celiac disease. A Phase 2a study investigating the efficacy and safety of anti-IL-15 in adults with celiac disease is ongoing (NCT06807463).
About Celiac Disease
Celiac disease is a chronic autoimmune disorder triggered by gluten, affecting the small intestine and leading to a range of symptoms. It can significantly impact an individual's quality of life, and diagnosis can be challenging. A strict, lifelong gluten-free diet is the only current treatment and even if adhering to a gluten-free diet, a significant proportion of patients still experience debilitating symptoms. In addition, trace amounts of gluten - especially through accidental or inadvertent ingestion - can cause severe reactions. Teva is dedicated to developing innovative medicines for immunological diseases, including celiac disease, with the goal of providing better health for people suffering from celiac disease worldwide.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to achieve expected results from investments in our product pipeline including to successfully develop and commercialize our anti-IL 15 (TEV-53408) asset for the treatment of people with celiac disease on a gluten-free diet; the risk that we will incur significant costs in connection with the development of anti-IL 15 (TEV-53408), which may exceed any revenue generated by anti-IL 15 (TEV-53408); risks that regulatory approvals and other requirements may delay the development and commercialization of our anti-IL 15 (TEV-53408); our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned 'Risk Factors and 'Forward Looking Statements.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
References
Gatti S, Rubio-Tapia A, Makharia G, Catassi C. Patient and Community Health Global Burden in a World with More Celiac Disease. Gastroenterology. 2024;167(1):23-33.
Singh, Prashant et al. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2018; 16(6), 823 - 836.e2
Mustalahti, K., Catassi, C., Reunanen, A., Fabiani, E., Heier, M., … McMillan, S. (2010). The prevalence of celiac disease in Europe: Results of a centralized, international mass screening project. Annals of Medicine, 2010; 42(8), 587–595.
Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Medtronic (MDT) is a Top Value Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Why Investors Should Pay Attention to This Value Stock Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks. Medtronic (MDT) In 2015, Medtronic, Inc. (the legacy NYSE-listed parent company, incorporated in Minnesota) acquired Ireland-based Covidien plc for cash and stock of $49.9 billion. The acquisition resulted in the formation of a new holding company incorporated in Ireland called Medtronic plc (the new Irish tax resident, NYSE-listed parent company holding both the legacy Medtronic and Covidien). MDT sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of B. Compared to the Medical - Products industry's P/E of 18.5X, shares of Medtronic are trading at a forward P/E of 16.2X. MDT also has a PEG Ratio of 2.3, a Price/Cash Flow ratio of 11.6X, and a Price/Sales ratio of 3.4X. Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0 to $5.55. MDT has an average earnings surprise of 2.2%. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding MDT to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
Commercial trial demonstrates SaFeGuard's™ effectiveness in processing opportunity crudes HOUSTON, August 20, 2025--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. "We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations," said Ketjen's Chief Commercial Officer Henri Tausch. "This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers." "SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon," said David Leach, Vice President and General Manager, FCC at Ketjen. "It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement." Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit View source version on Contacts Media Contact: Jennifer Albert, MediaRelations@ Sign in to access your portfolio
